Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) today announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Dicerna Receives Recommendation from EMA Committee to Designate DCR-PHXC an Orphan Medicinal Product for the Treatment of Primary Hyperoxaluria (PH) in the EUJuly 11, 2018 7:30 AM